JP2019533019A - Ｔｈｒ−ベータアゴニストで肝臓障害又は脂質障害を治療する方法 - Google Patents

Ｔｈｒ−ベータアゴニストで肝臓障害又は脂質障害を治療する方法 Download PDF

Info

Publication number
JP2019533019A
JP2019533019A JP2019542355A JP2019542355A JP2019533019A JP 2019533019 A JP2019533019 A JP 2019533019A JP 2019542355 A JP2019542355 A JP 2019542355A JP 2019542355 A JP2019542355 A JP 2019542355A JP 2019533019 A JP2019533019 A JP 2019533019A
Authority
JP
Japan
Prior art keywords
compound
subject
biomarker
dose
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019542355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533019A5 (https=
Inventor
タウブ，レベッカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madrigal Pharmaceuticals Inc
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of JP2019533019A publication Critical patent/JP2019533019A/ja
Publication of JP2019533019A5 publication Critical patent/JP2019533019A5/ja
Priority to JP2023157999A priority Critical patent/JP2024001055A/ja
Priority to JP2025079296A priority patent/JP2025122012A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019542355A 2016-10-18 2017-10-18 Ｔｈｒ−ベータアゴニストで肝臓障害又は脂質障害を治療する方法 Pending JP2019533019A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023157999A JP2024001055A (ja) 2016-10-18 2023-09-22 Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法
JP2025079296A JP2025122012A (ja) 2016-10-18 2025-05-12 Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662409833P 2016-10-18 2016-10-18
US62/409,833 2016-10-18
US201762516594P 2017-06-07 2017-06-07
US62/516,594 2017-06-07
PCT/US2017/057203 WO2018075650A1 (en) 2016-10-18 2017-10-18 Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023157999A Division JP2024001055A (ja) 2016-10-18 2023-09-22 Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法

Publications (2)

Publication Number Publication Date
JP2019533019A true JP2019533019A (ja) 2019-11-14
JP2019533019A5 JP2019533019A5 (https=) 2020-11-19

Family

ID=60480362

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019542355A Pending JP2019533019A (ja) 2016-10-18 2017-10-18 Ｔｈｒ−ベータアゴニストで肝臓障害又は脂質障害を治療する方法
JP2023157999A Pending JP2024001055A (ja) 2016-10-18 2023-09-22 Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法
JP2025079296A Pending JP2025122012A (ja) 2016-10-18 2025-05-12 Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023157999A Pending JP2024001055A (ja) 2016-10-18 2023-09-22 Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法
JP2025079296A Pending JP2025122012A (ja) 2016-10-18 2025-05-12 Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法

Country Status (12)

Country Link
US (3) US11090308B2 (https=)
EP (2) EP3528817B1 (https=)
JP (3) JP2019533019A (https=)
KR (2) KR20230156159A (https=)
CN (1) CN110167557A (https=)
AU (1) AU2017346871B2 (https=)
CA (1) CA3040888A1 (https=)
DK (1) DK3528817T3 (https=)
ES (1) ES2924257T3 (https=)
IL (2) IL302336B2 (https=)
MX (1) MX394463B (https=)
WO (1) WO2018075650A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024506848A (ja) * 2021-02-01 2024-02-15 マドリガル ファーマシューティカルズ インコーポレイテッド 肝障害又は脂質障害の治療のためのロスバスタチンとレスメチロムの治療的組み合わせ

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
WO2018075650A1 (en) 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
CN110627773B (zh) * 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
AR115666A1 (es) * 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CA3111025C (en) * 2018-09-06 2023-10-31 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
PT3911647T (pt) * 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CN113474335B (zh) * 2019-02-21 2024-12-03 南京瑞捷医药科技有限公司 化合物及其作为甲状腺激素受体激动剂的用途
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
AU2020336272A1 (en) * 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) * 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
WO2021104288A1 (zh) * 2019-11-26 2021-06-03 昆药集团股份有限公司 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用
CN111562321B (zh) * 2020-04-16 2022-10-28 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
WO2022052822A1 (zh) * 2020-09-10 2022-03-17 苏州科睿思制药有限公司 Resmetirom的晶型及其制备方法和用途
EP4204419A1 (en) 2020-10-19 2023-07-05 Teva Pharmaceuticals International GmbH Solid state forms of resmetirom
US20250000836A1 (en) * 2021-07-21 2025-01-02 Cyta Therapeutics, Inc. Particle delivery of thyroid hormone receptor agonists and antagonists
PE20241327A1 (es) * 2021-11-11 2024-06-26 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-beta
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2024263714A1 (en) * 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
WO2025083699A2 (en) 2023-10-16 2025-04-24 Cipla Limited Resmetirom polymorphs and process thereof
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom
CN121648128A (zh) * 2026-02-03 2026-03-13 华中科技大学同济医学院附属同济医院 特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123256A1 (en) * 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US20080152700A1 (en) 2004-06-01 2008-06-26 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US7807647B2 (en) 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
DK1919878T3 (da) 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
HRP20100611T1 (hr) 2007-06-06 2010-12-31 Torrent Pharmaceuticals Ltd Novi spojevi
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
WO2018075650A1 (en) 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
AR115666A1 (es) 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123256A1 (en) * 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, JPN6021030590, 2014, pages 3912 - 3923, ISSN: 0005063663 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, JPN7022001702, 2009, pages 1152 - 1163, ISSN: 0005063664 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024506848A (ja) * 2021-02-01 2024-02-15 マドリガル ファーマシューティカルズ インコーポレイテッド 肝障害又は脂質障害の治療のためのロスバスタチンとレスメチロムの治療的組み合わせ

Also Published As

Publication number Publication date
IL302336A (en) 2023-06-01
MX394463B (es) 2025-03-19
JP2025122012A (ja) 2025-08-20
AU2017346871B2 (en) 2023-08-03
CA3040888A1 (en) 2018-04-26
JP2024001055A (ja) 2024-01-09
DK3528817T3 (da) 2022-08-08
IL266054A (en) 2019-06-30
EP4112056A1 (en) 2023-01-04
AU2017346871A1 (en) 2019-05-02
EP3528817A1 (en) 2019-08-28
IL266054B2 (en) 2023-10-01
MX2019004492A (es) 2019-11-18
US20210330675A1 (en) 2021-10-28
KR20230156159A (ko) 2023-11-13
CN110167557A (zh) 2019-08-23
IL302336B1 (en) 2025-07-01
ES2924257T3 (es) 2022-10-05
IL302336B2 (en) 2025-11-01
US11090308B2 (en) 2021-08-17
EP4112056B1 (en) 2026-01-21
US20240156826A1 (en) 2024-05-16
KR20190109387A (ko) 2019-09-25
WO2018075650A1 (en) 2018-04-26
IL266054B1 (en) 2023-06-01
US20200230146A1 (en) 2020-07-23
US11806353B2 (en) 2023-11-07
EP3528817B1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
US11806353B2 (en) Methods of treating liver disorders or lipid disorders with a THR-beta agonist
US12383530B2 (en) Pharmaceutical combination for the treatment of melanoma
US20200339591A1 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN103501785B (zh) 用于治疗脑肿瘤的csf-1r抑制剂
JP2019533019A5 (https=)
EA021731B1 (ru) Новые композиции для лечения болезни альцгеймера
HK1208823A1 (en) Modulation of hepatitis b virus cccdna transcription
EA019571B1 (ru) Применение сульфизоксазола для лечения болезни альцгеймера
EA034869B1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
ES2991090T3 (es) Inhibidores de KDM4
US20180169078A1 (en) Small Molecule Analogs of the Nemo Binding Peptide
US20190119684A1 (en) Methods for improving cognitive function via modulation of quinone reductase 2
US20230190718A1 (en) Methods for the treatment of pancreatitis and prevention of pancreatic cancer
CN116271033B (zh) 一种以sqle基因或蛋白为靶点治疗克唑替尼肝脏毒性的药物
US20250288572A1 (en) Compositions and methods for treating pulmonary vascular disease
CN119345327A (zh) 双受体激动剂在结直肠癌治疗中的用途
CN120936368A (zh) β-连环蛋白拮抗剂的施用和使用方法
CN117320701A (zh) 一种降低肝脏中甘油三酯合成的方法
Ting Pharmacokinetics and limited sampling strategies of mycophenolic acid in lung transplant recipients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230523